CAPS is due to gain-of-function mutations in NLRP3, a major protein of the inflammasome platform that activates pro-caspase-1 into its active form caspase 1, which in turn promotes the processing of the potent pro-inflammatory cytokine interleukin-1β [12]. The gene discussed is NLRP3; the disease is cryopyrin-associated periodic syndrome.